Does Wegovy lower cortisol levels — and does it matter for weight loss?

What does cortisol actually do, and why do people think Wegovy might affect it?

Cortisol is a hormone released by the adrenal glands, most commonly in response to stress, low blood sugar, or disrupted sleep. In short bursts it is useful, it sharpens focus and mobilises energy. Chronically elevated cortisol is a different matter. It encourages the body to store fat preferentially around the abdomen, raises appetite (particularly for calorie-dense foods), and can blunt the hormonal signals that tell you you're full.

That last point is why the question keeps coming up. Wegovy works partly by amplifying satiety signals through GLP-1 receptors in the gut and brain, and some people reasonably wonder whether it might also quieten the stress-related drive to eat. The two systems do interact at the level of the hypothalamus, which co-ordinates both appetite and the stress response. That biological overlap is enough to make the question scientifically interesting. It is not, however, enough to call semaglutide a cortisol-lowering medicine.

The NHS patient information on semaglutide describes its action clearly: it mimics the hormone GLP-1 to reduce appetite and slow gastric emptying. Cortisol regulation sits in a different pathway entirely, and if you want to understand the relationship in more depth, our page on how semaglutide and cortisol interact covers the evidence in plain terms. For more on what semaglutide does and does not do in the body, our semaglutide overview covers the mechanism in plain terms.

Does losing weight on Wegovy bring cortisol down as a side-effect of the weight loss itself?

This is where the picture gets more nuanced. There is reasonable observational evidence that excess body fat (particularly visceral (abdominal) fat) is associated with higher cortisol activity. Fat tissue, especially around the organs, contains enzymes that can regenerate cortisol locally, meaning people carrying more abdominal weight may have higher cortisol exposure at the tissue level even when blood tests look normal.

If Wegovy helps someone lose a meaningful amount of abdominal fat, it is plausible that some of that local cortisol activity reduces too. A few small studies have explored this, and results have been mixed. None have been large enough or long enough to draw firm conclusions, and none were conducted specifically with Wegovy at its licensed dose. If you want to explore the specific question of whether Wegovy lowers cortisol levels, we have looked at what the available research actually shows. The honest summary: weight loss may help, but semaglutide is not a cortisol treatment and has not been studied or approved as one.

There is also a practical timing point worth making. People often start thinking about weight management after a stressful period, after a difficult few months at work, or once the post-holiday dust settles. Stress and weight gain tend to track together. Starting treatment during a high-cortisol phase of life does not mean the medicine will fix the stress, but it may help interrupt one part of the cycle.

For a related question about how semaglutide affects blood sugar (another metabolic marker that cortisol influences) take a look at our page on whether Wegovy lowers blood sugar.

Should high cortisol affect which weight-loss medicine you're offered, or whether you're offered one at all?

Sometimes, yes. Genuinely elevated cortisol with a physiological cause (Cushing's syndrome being the clearest example) can produce weight gain that does not respond well to appetite-based medicines alone. In that situation, treating the underlying cortisol excess is the priority, and a prescriber would need to know about it before approving any weight-management medicine.

For the much more common picture of mildly elevated cortisol driven by chronic stress, poor sleep, or irregular eating, the situation is different. There is no blanket contraindication to GLP-1 medicines in that context. A prescriber will look at the whole picture: your weight, your health history, any conditions that affect eligibility, and what you've already tried.

This is why nume's consultations are reviewed by a GPhC-registered prescriber rather than an automated system, questions like this one require clinical judgment, not a tick-box form. If cortisol levels or adrenal health are part of your picture, our team can factor that in. The Wegovy treatment page sets out what the consultation covers and what to expect from the process. You can also read about the broader range of weight-loss treatment options we assess people for, in case a different approach fits better.

What should you do if you're worried about cortisol and want to explore weight-loss treatment?

Start by being honest in your consultation. If you suspect high cortisol (whether because of persistent abdominal weight, fatigue, poor sleep, or a formal test result) say so. A prescriber can assess whether further investigation makes sense and whether semaglutide is appropriate for you right now.

If you have already had cortisol levels checked and they were elevated, bring that information. It does not automatically exclude you from treatment, but it changes the clinical conversation. The MHRA's published guidance on GLP-1 medicines is clear that these are not assessed or approved for cortisol management, and the Yellow Card scheme remains the channel for reporting any unexpected hormonal effects you notice once on treatment.

You may also want to look at the broader hormonal context. Semaglutide's effects on blood pressure are another question that comes up alongside cortisol, and our page on Wegovy and blood pressure covers that in detail. For a fuller picture of what our clinical team considers, the clinical oversight page explains who reviews your consultation and how.

If you'd like to explore whether Wegovy is suitable for you, speak to our prescribers through a free consultation, the same day if you submit before noon on a weekday.